China Universal Asset Management Co. Ltd. Acquires 412 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

China Universal Asset Management Co. Ltd. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 10.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,457 shares of the specialty pharmaceutical company’s stock after acquiring an additional 412 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in ANI Pharmaceuticals were worth $246,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ANIP. Thrivent Financial for Lutherans raised its position in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after acquiring an additional 300 shares during the period. Exchange Traded Concepts LLC boosted its holdings in ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after acquiring an additional 310 shares during the last quarter. New York State Teachers Retirement System increased its position in ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares during the period. Finally, State of Alaska Department of Revenue raised its holdings in ANI Pharmaceuticals by 5.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock worth $564,000 after purchasing an additional 464 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,381 shares of company stock worth $2,441,556 over the last quarter. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $58.64 on Monday. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.23 billion, a PE ratio of -106.62 and a beta of 0.73. The business’s 50-day moving average price is $56.61 and its two-hundred day moving average price is $58.53.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the business posted $1.05 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ANIP. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 28th. Finally, Truist Financial increased their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.